Results from Bevacizumab, an anti-VEGFA mAb, in combination with atezolizumab demonstrated ORR of 64% and medium duration of response of 10.4 months as a first-line chemo-free therapy in NSCLC with PD-L1 expression >50% (46). The gene discussed is CD274; the disease is non-small cell lung carcinoma.